Expression profiling of primary and metastatic oral squamous cell carcinoma identifies progression-associated transcriptome changes and therapeutic vulnerabilities

Jonas Pyko; Markus Glaß; Julia Rosemann; Matthias Kappler; Jana Macho; Sarah Qasem; Stefan Hüttelmaier; Alexander W. Eckert; Monika Haemmerle; Tony Gutschner

doi:10.1002/cac2.12660

Cancer Communications ›› 2025, Vol. 45 ›› Issue (4) :433 -437. DOI: 10.1002/cac2.12660

LETTER TO THE JOURNAL

Expression profiling of primary and metastatic oral squamous cell carcinoma identifies progression-associated transcriptome changes and therapeutic vulnerabilities

Author information +

History +

PDF

Cite this article

Download citation ▾

Jonas Pyko, Markus Glaß, Julia Rosemann, Matthias Kappler, Jana Macho, Sarah Qasem, Stefan Hüttelmaier, Alexander W. Eckert, Monika Haemmerle, Tony Gutschner. Expression profiling of primary and metastatic oral squamous cell carcinoma identifies progression-associated transcriptome changes and therapeutic vulnerabilities. Cancer Communications, 2025, 45(4): 433-437 DOI:10.1002/cac2.12660

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Lee H, Roh JL, Cho KJ, Choi SH, Nam SY, Kim SY. Number of positive lymph nodes better predicts survival for oral cavity cancer. J Surg Oncol. 2019; 119(6): 675-682.

[2]	Shah JP. Cervical lymph node metastases–diagnostic, therapeutic, and prognostic implications. Oncology (Williston Park). 1990; 4(10): 61-69; discussion 72, 6.

[3]	Zanoni DK, Montero PH, Migliacci JC, Shah JP, Wong RJ, Ganly I, et al. Survival outcomes after treatment of cancer of the oral cavity (1985-2015). Oral Oncol. 2019; 90: 115-521.

[4]	Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517(7536): 576-582.

[5]	Ducker GS, Ghergurovich JM, Mainolfi N, Suri V, Jeong SK, Hsin-Jung Li S, et al. Human SHMT inhibitors reveal defective glycine import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2017; 114(43): 11404-11409.

[6]	Liao Y, Wang F, Zhang Y, Cai H, Song F, Hou J. Silencing SHMT2 inhibits the progression of tongue squamous cell carcinoma through cell cycle regulation. Cancer Cell Int. 2021; 21(1): 220.

[7]	Zhang H, Che Y, Xuan B, Wu X, Li H. Serine hydroxymethyltransferase 2 (SHMT2) potentiates the aggressive process of oral squamous cell carcinoma by binding to interleukin enhancer-binding factor 2 (ILF2). Bioengineered. 2022; 13(4): 8785-8797.

[8]	di Micco P, Antolin AA, Mitsopoulos C, Villasclaras-Fernandez E, Sanfelice D, Dolciami D, et al. canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Res. 2023; 51(D1): D1212-D1219.

[9]	Prgomet Z, Axelsson L, Lindberg P, Andersson T. Migration and invasion of oral squamous carcinoma cells is promoted by WNT5A, a regulator of cancer progression. J Oral Pathol Med. 2015; 44(10): 776-784.

[10]	Goesswein D, Habtemichael N, Gerhold-Ay A, Mazur J, Wunsch D, Knauer SK, et al. Expressional analysis of disease-relevant signalling-pathways in primary tumours and metastasis of head and neck cancers. Sci Rep. 2018; 8(1): 7326.